Tenaya Therapeutics Inc TNYA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-30 |
| Shares Out. | 217,000,000 |
| Website | tenayatherapeutics.com/ ↗ |
| Phone | 14158652066 |
| Employees | 70 |
| Revenue | $225,000 |
| Gross Profit | $225,000 |
| Net Income | -$19.3M |
| Free Cash Flow | -$64.6M |
| Total Assets | $135.1M |
| Total Liabilities | $28.9M |
| Equity | $106.2M |
About Tenaya Therapeutics Inc
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Tenaya Therapeutics Inc is a publicly traded company under the ticker symbol TNYA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)